Moreover, Ferrao et al. [3] demonstrated the benefits and efficacy of treating Myc-driven lymphomas with single agent Chk inhibitor and showed that the dual Chk1-Chk2 inhibitor was more powerful in p53 deficient cells than the Chk1 inhibitor alone. This evidence concerns the gene CHEK1 and lymphoma.